

Ref: Akums/Exchange/2025-26/52

November 03, 2025

To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

To,
The Listing Department
BSE Limited
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Fort, Mumbai -
400 001

Symbol: AKUMS

Scrip Code: 544222

Sub: **Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Grant of Patent**

Respected Sir/Madam,

Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015, we would like to inform you that a patent has been granted to the Company for an invention entitled **"Dual Release Gastro-Resistant Composition"** for the term of 20 years from 19th November, 2022 in accordance with the provisions of the Patents Act, 1970.

The Company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment-resistant gastroesophageal reflux disease (GERD) - one of the most common digestive disorders globally. GERD affects nearly **14% of the global population**, with an estimated **784 million people** living with the condition as of 2019, In **India**, recent meta-analyses estimate a pooled prevalence of **15.6%**.

GERD occurs when stomach acid frequently flows back into the esophagus, causing heartburn and discomfort. PPIs such as Pantoprazole and Esomeprazole are highly effective in reducing stomach acid and healing acid-related damage. However, conventional PPIs may not last long enough, leading to **nocturnal acid breakthrough** and incomplete symptom relief.

AKUMS

DRUGS & PHARMACEUTICALS LTD.



Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

+91-11-69041000

CIN: L24239DL2004PLC125888

www.akums.in

akumsho@akums.net

+91-11-27023256

To overcome this, Akums has developed Dual Release PPI tablets that release the medicine in two phases 50% in the duodenum and 50% in the ileum, and hence an extended absorption of drug, and hence extended duration of action. Therefore, dual release gastro resistant tablet of PPI has been designed to provide better heartburn free days (daytime or night time), long-lasting heartburn relief, improved compliance, and enhanced quality of life with just one tablet a day.

Using unique tablet-in-tablet technology, this formulation offers better stability, uniform drug release, and improved formulation attributes. This advanced, once-daily formulation has received DCGI approval and reinforces Akums' commitment to developing innovative and patient-friendly therapies for chronic acid-related disorders.

Copy of the Patent Certificate is attached herewith for your kind reference.

This is for your kind information and record.

Thanking You

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik
Company Secretary & Compliance Officer

Encl: as above

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256



सत्यमेव जयते



The Patent Office, Government Of India

Patent Certificate

(Rule 74 of The Patents Rules)

573119

202211066513

19/11/2022

AKUMS DRUGS & PHARMACEUTICALS LIMITED

It is hereby certified that a patent has been granted to the patentee for an invention entitled *DUAL RELEASE GASTRO-RESISTANT COMPOSITION* as disclosed in the above mentioned application for the term of 20 years from the 19th day of November 2022 in accordance with the provisions of the Patents Act, 1970.

It is hereby certified that a patent has been granted to the patentee for an invention entitled *DUAL RELEASE GASTRO-RESISTANT COMPOSITION* as disclosed in the above mentioned application for the term of 20 years from the 19th day of November 2022 in accordance with the provisions of the Patents Act, 1970.



पेटेंट नियंत्रक
Controller of Patents

Note. - The fees for renewal of this patent, if it is to be maintained, will fall / has fallen due on 19th day of November 2024 and on the same day in every year thereafter.